Report Library
All ReportsDatamonitor Healthcare Oncology: Acute Myeloid Leukemia (AML) Disease Coverage
April 11, 2018
Acute myeloid leukemia (AML) is a hematological malignancy characterized by the proliferation of myeloid blast cells in blood and bone
marrow. There has been little change to standard treatment for AML, which is typically based on cytarabine chemotherapy with an
anthracycline. Although patients aged <60 years may achieve remission with induction therapy, most patients will relapse, and the prognosis
worsens with age.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.
Indications Covered: | Acute Myelogenous Leukemia (AML) |